Robin Carhart-Harris

There's just a widespread in science now, there's a greater sensitivity to the possibility that results will not replicate.

There's obviously a replication crisis so branded in

the social sciences and psychology.

What's your sense of the quality of the evidence that we're hurling at the FDA or likely to hurl in the near future so as to argue for the therapeutic value and legalization?

Well, there's a lot of small studies published.

A few of them have come from myself and my colleagues.

And what's happened historically is that this space has been up against it.

So we've

done everything that we can to raise money.

And much of that's come from philanthropy and typically running an investigator-led study, so not an industry-sponsored study or trial.

You've got a limited budget and you set something up and it's 20 patients and you kind of sow the seed.

And so that's what we did back in 2016 with psilocybin therapy for treatment-resistant depression.

So most of the trials in this modern era have been published in the last 20 years.

Really, the first clinical trial in the clinical population was 2006.

That was Francesco Moreno looking at psilocybin for obsessive compulsive disorder.

And yeah, so there are probably now, I would estimate, a couple of dozen small trials and a couple of biggies.

We've got the Phase 2b work of Compass Pathways, and we're also hearing the top line findings from their Phase 3 works.

So that takes us into the hundreds in a single trial, albeit multi-site.

Are these for psilocybin?

This is psilocybin therapy for treatment-resistant depression.